Pharsight

Janumet is owned by Merck Sharp Dohme.

Janumet contains Metformin Hydrochloride; Sitagliptin Phosphate.

Janumet has a total of 8 drug patents out of which 4 drug patents have expired.

Expired drug patents of Janumet are:

US7125873
US6699871*PED
US7125873*PED
US6699871

Janumet was authorised for market use on 30 March, 2007.

Janumet is available in tablet;oral dosage forms.

Janumet can be used as method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin; method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin; method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with metformin and a ppar-gamma agonist, method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor, method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin.

The generics of Janumet are possible to be released after 21 January, 2029.

Application	Filing Date	Opposition Party	Legal Status
EP05077584A	2011-03-15	APOTEX INC.	Revoked
EP04755691A	2008-06-11	Teva Pharmaceutical Industries Ltd.	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US7326708	June, 2020	FWD Entered	Merck Sharp & Dohme Corp.	Sun Pharmaceutical Industries Ltd.
US7326708	June, 2020	FWD Entered	Merck Sharp & Dohme Corp.	Dr. Reddy's Laboratories, Inc.
US7326708	June, 2020	Terminated-Settled	Merck Sharp & Dohme Corp.	Teva Pharmaceuticals USA, Inc.
US7326708	October, 2019	FWD Entered	Merck Sharp & Dohme Corp.	Mylan Pharmaceuticals, Inc.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871	MERCK SHARP DOHME	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	Jul, 2022 (8 months ago)
US7326708	MERCK SHARP DOHME	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	Nov, 2026 (3 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7125873	MERCK SHARP DOHME	Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	Jul, 2022 (8 months ago)
US6699871 (Pediatric)	MERCK SHARP DOHME	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	Jan, 2023 (a month ago)
US7125873 (Pediatric)	MERCK SHARP DOHME	Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	Jan, 2023 (a month ago)
US7326708 (Pediatric)	MERCK SHARP DOHME	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	May, 2027 (4 years from now)
US8414921	MERCK SHARP DOHME	Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin	Jul, 2028 (5 years from now)
US8414921 (Pediatric)	MERCK SHARP DOHME	Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin	Jan, 2029 (5 years from now)

Exclusivity	Exclusivity Expiration
M (M)	Dec 4, 2023
Pediatric Exclusivity (PED)	Jun 4, 2024

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 30 March, 2007

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin; Method of treating type 2 diabetes mellitus by administering a dipeptidyl p...

Dosage: TABLET;ORAL